NKGN (NKGen Biotech) Insider Ownership : 0.56 % (As of Mar. 03, 2025)

View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, NKGen Biotech's insider ownership is 0.56%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, NKGen Biotech's Institutional Ownership is 23.62%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, NKGen Biotech's Float Percentage Of Total Shares Outstanding is 60.55%.

NKGen Biotech Insider Ownership Historical Data

The historical data trend for NKGen Biotech's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Insider Ownership Chart

NKGen Biotech Historical Data

The historical data trend for NKGen Biotech can be seen below:

	2024-04-30	2024-05-31	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31
Insider Ownership	0.87	0.80	0.77	0.77	0.77	0.56	0.56	0.56	0.56	0.56

NKGen Biotech Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

NKGen Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

3001 Daimler Street, Santa Ana, CA, USA, 92705

Website

https://www.nkgenbiotech.com

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.